Therapy-induced senescence contributes to the efficacy of abemaciclib in patients with dedifferentiated liposarcoma

• Main Authors: Gleason, Caroline E., Dickson, Mark A., Klein, Mary E. (Dooley), Antonescu, Cristina R., Gularte-Mérida, Rodrigo, Benitez, Marimar, Delgado, Juliana I., Kataru, Raghu P., Tan, Mark Wei Yi, Bradic, Martina, Adamson, Travis E., Seier, Kenneth, Richards, Allison L., Palafox, Marta, Chan, Eric, D'Angelo, Sandra P., Gounder, Mrinal M., Keohan, Mary Louise, Kelly, Ciara M., Chi, Ping, Movva, Sujana, Landa, Jonathan, Crago, Aimee M., Donoghue, Mark T. A., Qin, Li-Xuan, Serra, Violetta, Turkekul, Mesruh, Barlas, Afsar, Firester, Daniel M., Manova-Todorova, Katia, Mehrara, Babak J., Kovatcheva, Marta, Tan, Nguan Soon, Singer, Samuel, Tap, William D., Koff, Andrew
• 其他作者: Lee Kong Chian School of Medicine (LKCMedicine)
• 格式: Article
• 語言: English
• 出版: 2024
• 主題: Medicine, Health and Life Sciences; Dedifferentiated liposarcoma; DNA microarray
• 在線閱讀: https://hdl.handle.net/10356/180081
• 機構: Nanyang Technological University

Purpose: We conducted research on CDK4/6 inhibitors (CDK4/6i) simultaneously in the preclinical and clinical spaces to gain a deeper understanding of how senescence influences tumor growth in humans. Patients and Methods: We coordinated a first-in-kind phase II clinical trial of the CDK4/6i abemacic...